Treatment-resistant Depression Clinical Trial
Official title:
A Prospective Study on the Psychosocial Characteristics and Non-pharmacological Intervention of Patients With Treatment-resistant Depression
Verified date | June 2020 |
Source | National Taiwan University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Pharmacotherapy and psychotherapy, effective management strategies for treatment-resistant depression are limited and yet to be developed. However, nursing interventions focusing on adherence enhancement, symptom reduction, and stress management may be strategic for a better disease management. This study aimed to define the rarely-studied concept of TRD under the cultural context of Taiwan and to identify new feasible and complementary treatment model from nursing perspectives. The project had established important basis on the descriptions of psychosocial features and need assessment of people with TRD over psychiatrist's validation. The findings also built up a cultural-specific non-pharmacological intervention module for effective TRD management in Taiwan. The nursing model of TRD management will further promote the development of integrative depression care in the future and complement current modalities, while providing important evidence-based information for future research and services.
Status | Completed |
Enrollment | 46 |
Est. completion date | October 30, 2020 |
Est. primary completion date | September 22, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. Aged 20-85 ; 2. To be diagnosed with Major Depressive disorder or Bipolar II disorder; 3. Failed to respond to at least three weeks of two antidepressant trials ; 4. Able to communicate with Mandarin or Taiwanese ; 5. No severe or foreseeing cognitive impairment during study period judged by the co-PI; 6. Willing to sign the informed consent. Exclusion Criteria: 1. Unable to cooperate due to psychiatric symptom disturbance ; 2. Unwilling to provide most information in the questionnaire ; 3. Severely suicidal during study period |
Country | Name | City | State |
---|---|---|---|
Taiwan | Chia-Yi Wu | Taipei |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital | Shin Kong Wu Ho-Su Memorial Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of score of the Brief Symptom Rating Scale(BSRS-5) for psychological distress level | The full scale contains five items of psychopathology: (1) anxiety; (2) depression; (3) hostility; (4) interpersonal sensitivity: inferiority; and (5) insomnia. An extra question "Do you have any suicide ideation?" is added at the end of the scale. It is a 5-item Likert scale (scores of 0 to 4) for assessment of psychological distress level by self-report of by interview. The rating of symptoms is based on a 5-point scale: 0, not at all; 1, a little bit; 2, moderately; 3, quite a bit; 4, extremely. Total score will be calculated based on the 5 questions with a maximum score of 20, where a higher score indicates higher level of psychological distress and poorer mental health status in the past week. | Baseline assessment and follow up sessions on 3,6, and 9 months | |
Primary | The change of score in 9-item Concise Mental Health Checklist (CMHC-9) for suicide risk assessment | The CMHC-9 is consisted of 9 items assessing psychopathgology (5 items) and suicide risk (4 items). The five item evaluated recent mental distress, lending the measurement from the BSRS-5, i.e., insomnia, anxiety, hostility, depression, and inferiority. The four items reflecting several key suicide risk factors, including lifetime suicide attempt, future suicide intent, alcohol or drug abuse history, and lack of social support. Each item was rated by 0/1, indicating the existence of each symptom, with a total score ranging from 0 to 9. The higher the score, the higher the risk of suicide. The cutoff at 4 points indicates a higher overall suicide risk among clinical or community population. | Baseline assessment and follow-up session on the 9th month | |
Primary | Change of score in Brief Resilience Coping Scale (BRCS) for tendencies to cope with stress | It is a 4-item measurement tool designed to assess the ability of an individual to cope with stress in a resilient fashion. The response consists of five options at which 1 means the statement "does not describe you at all" and 5 means "it describes you very well". The score is then added up.Among general public, the score of 4-13 indicates low resilient copers; 14-16 indicates medium resilient copers; and 17-20 indicates high resilient copers. However, the scores will undergo validation among a cohort of TRD patients in this study. | Baseline assessment and follow up sessions on 3,6, and 9 months | |
Secondary | Community Integration Questionnaire-Revised (CIQ-R) for the participants' level of community integration | CIQ-R consists of four domains: home integration, social integration, productivity, andelectronic social networking score. The scale contains 18 items. The home integration subscale is made up of 5 items at which each item is scored from 0-2, where 2 indicates highest degree of integration. The Social Integration subscale consists 6 items with the same scoring method mentioned above. The productivity subscale consists of 4 questions with a total points of 7. The electronic social networking subscale consists of 3 questions with a total points of 6. Scores of these subscales are then added up as an overall CIQ score. Maximum score is 35, which represents maximum community reintegration. | Follow up sessions on 3, 6, and 9 months | |
Secondary | EQ-5D questionnaire for quality of life | The EQ-5D is a self-completed questionnaire which contains five dimensions: mobility, self-care, usual activities, pain-discomfort, and anxiety-depression. The level of function in each dimension is classified into three degrees of disability, which is level 1(no disability), level 2(moderate disability), and level 3(severe disability). These responses will then generate a 5-digit descriptor ranging from 1-1-1-1-1 indicating perfect health to 3-3-3-3-3 indicating worth possible state. It is accompanied by a visual analogue scale (EQ-VAS) to assess perceived health conditions, which ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). | Follow up sessions on 3, 6, and 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02497287 -
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
|
Phase 3 | |
Recruiting |
NCT03653858 -
Efficacy Study of Deep Brain Stimulation in Patients With Treatment Resistant Major Depression
|
N/A | |
Recruiting |
NCT01868802 -
Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population
|
Phase 2 | |
Recruiting |
NCT02462551 -
Focal Electrically Administered Seizure Therapy for the Treatment of Depression
|
N/A | |
Recruiting |
NCT05377177 -
Cortical Inhibition as a Biomarker of Response in a Comparison of Bilateral Versus Unilateral Accelerated Theta Burst Stimulation for Suicidal Ideation in Treatment-Resistant Depression -COMBAT-SI
|
N/A | |
Completed |
NCT05095792 -
Effect of Ketamine on Neurological Activity as Measured by Electroencephalogram (EEG)
|
||
Recruiting |
NCT06372834 -
Adjuvant Accelerated piTBS for Reducing Suicidal Ideation in TRD Patients
|
N/A | |
Active, not recruiting |
NCT03701724 -
Cost-utility Analysis of Maintenance rTMS for Treatment-resistant Depression
|
N/A | |
Recruiting |
NCT05800860 -
A Trial of GH001 in Patients With Treatment-resistant Depression
|
Phase 2 | |
Not yet recruiting |
NCT06404320 -
Physical Activity Program for TRD
|
N/A | |
Completed |
NCT01945047 -
Action of Ketamine in Treatment-Resistant Depression
|
Phase 2/Phase 3 | |
Recruiting |
NCT05045378 -
Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression
|
Phase 4 | |
Completed |
NCT05454410 -
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
|
Phase 2 | |
Recruiting |
NCT05422417 -
Dorsomedial Prefrontal Neuromodulation in Treatment-resistant Depression
|
N/A | |
Recruiting |
NCT05842291 -
pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression
|
N/A | |
Recruiting |
NCT04821271 -
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
|
Phase 2 | |
Active, not recruiting |
NCT04670081 -
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression
|
Phase 2 | |
Terminated |
NCT01598324 -
Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder
|
N/A | |
Recruiting |
NCT05710237 -
Does Psilocybin Require Psychedelic Effects to Treat Depression?
|
Phase 2 | |
Not yet recruiting |
NCT05661383 -
Olfactory and Brain Stimulations in Treatment-resistant Depression
|
N/A |